ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Aramchol? reduces fibrosis progression in 24 weeks EuropeanPharmaceuticalReview
November 02, 2021Galmed Pharmaceuticals has announced results from the first 16 patients in the open-label part of the ARMOR? Phase III study who underwent a scheduled post-baseline biopsy and were treated with Aramchol? for fibrosis. -
Galmed Initiated Study of Aramchol in Subjects with NASH and Fibrosis americanpharmaceuticalreview
September 27, 2019Galmed Pharmaceuticals announced the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled ...
Pharma Sources Insight January 2025
